Biocon’s Kiran picks a family member as successor

Biocon founder and chairperson Kiran Mazumdar-Shaw has set out a formal succession plan for the biotechnology company, naming her niece Claire Mazumdar as her chosen successor, according to an interview with Fortune India.

Mazumdar-Shaw, who founded Biocon over four decades ago and has no children, said she sees 37-year-old Claire Mazumdar as the right person to lead the next phase of the company’s growth, which will be driven by advanced biotechnology and artificial intelligence.

“I am the sole owner of Biocon, and I need to make sure that I put it in good hands,” Mazumdar-Shaw told Fortune India. “I have seen my niece Claire as my successor, because I think she has proved to me that she can run a company.”

Mazumdar-Shaw indicated that the transition would be gradual, saying in a post on X that she was “not planning to hang up my boots for a while” and that Claire would “gradually transition into my role in time,” signalling continuity in leadership even as succession plans take shape.

Claire Mazumdar is currently founder and CEO of Bicara Therapeutics, a NASDAQ-listed company incubated by Biocon. She holds degrees from MIT and Stanford, including a PhD in cancer biology, and previously worked with Third Rock Ventures and Rheos Medicines. Bicara was listed in 2024 and has a market capitalisation of over $1.6 billion.

Mazumdar-Shaw also outlined the broader family ecosystem that could support Biocon’s future, including Claire’s brother Eric Mazumdar, a Caltech professor and AI expert, and her husband Thomas Roberts, an oncologist at Massachusetts General Hospital.

As part of a wider organisational overhaul, Biocon has merged its generics and biologics businesses, reduced debt, and simplified its structure. The company is focusing on biosimilars, which account for around 60% of revenue, with 12 products already in the market and about 20 in the pipeline.

Leadership transitions are also underway across group companies. Shreehas Tambe has taken over as CEO and managing director of Biocon Biologics, while Siddharth Mittal is set to lead Syngene International from July 1.

Mazumdar-Shaw said the group’s future growth will be anchored in differentiated biosimilars, original biologic drugs, and deeper integration of artificial intelligence across research and development platforms.

Biocon share price rose on Tuesday and were last trading 1.23% higher at Rs 365.05, as of 11:49 a.m.